Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
Salmonella, Yersinia enterocolitica, Escherichia coli, Morganella spp., Proteus mirabilis, Proteus vulgaris, Shigella sonnei, and Klebsiella pneumoniae are among the Enterobacteriaceae that are resistant to cefodizim in vitro. Citrobacter freundii and Serratia marcescens are two Citrobacter species against which cefodizime has varying degrees of marginal inhibitory action. Other Gram-negative bacteria, such as Moraxella catarrhalis, Neisseria gonorrhoeae, Neisseria meningitidis, and Haemophilus influenzae, are inhibited by cefodizime [1]. The bactericidal antibiotic cefodizime has a strong affinity for Escherichia coli's penicillin-binding proteins 1A/B, 2, and 3. The lowest inhibitory concentration and the in vitro concentrations at which cefodizime is bactericidal against sensitive strains of Gram-positive and Gram-negative bacteria are often comparable [1].
|
---|---|
ln Vivo |
When mice were given a single subcutaneous dose of 50 mg/kg of cephalosporins, cefuroxime, or cefazolin, eight hours later, the activity of cefodizime was higher than that of cefoperazone, ceftazidime, and cefotaxime in an experimentally induced respiratory tract infection caused by Klebsiella pneumoniae. But unlike these cephalosporins, cefodizime has a noticeable bactericidal effect for a minimum of 48 hours following a single injection. Within 48 hours, 50% of the mice had completely cleared their lungs of all germs, even though cefodizime was no longer visible in their serum [1].
|
References |
|
Additional Infomation |
Cefodizime sodium is a cephalosporin.
Cefodizime Sodium is the sodium salt form of cefodizime, a third-generation, aminothiazolyl cephalosporin for parenteral use. Cefodizime has broad-spectrum activity and is stable to most beta-lactamases. |
Molecular Formula |
C20H18N6NA2O7S4
|
---|---|
Molecular Weight |
628.6325
|
Exact Mass |
627.991
|
CAS # |
86329-79-5
|
Related CAS # |
Cefodizime;69739-16-8
|
PubChem CID |
9852176
|
Appearance |
Off-white to light yellow solid powder
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
15
|
Rotatable Bond Count |
8
|
Heavy Atom Count |
39
|
Complexity |
1020
|
Defined Atom Stereocenter Count |
2
|
SMILES |
CC1=C(SC(=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-])CC(=O)[O-].[Na+].[Na+]
|
InChi Key |
WBOBLQIRACJNPA-AEKYOGSZSA-L
|
InChi Code |
InChI=1S/C20H20N6O7S4.2Na/c1-7-10(3-11(27)28)37-20(22-7)36-5-8-4-34-17-13(16(30)26(17)14(8)18(31)32)24-15(29)12(25-33-2)9-6-35-19(21)23-9;;/h6,13,17H,3-5H2,1-2H3,(H2,21,23)(H,24,29)(H,27,28)(H,31,32);;/q;2*+1/p-2/b25-12-;;/t13-,17-;;/m1../s1
|
Chemical Name |
disodium;(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[5-(carboxylatomethyl)-4-methyl-1,3-thiazol-2-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~100 mg/mL (~159.08 mM)
DMSO : ~62.5 mg/mL (~99.42 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 100 mg/mL (159.08 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.5908 mL | 7.9538 mL | 15.9076 mL | |
5 mM | 0.3182 mL | 1.5908 mL | 3.1815 mL | |
10 mM | 0.1591 mL | 0.7954 mL | 1.5908 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.